Vaccine Information Statement (VIS) -- Meningococcal ACWY Vaccines (MenACWY and MPSV4): What You Need to Know
This two-page Vaccine Information Statement (VIS) educates people about meningococcal vaccines. It explains that the serogroups A, B, C, W, and Y of the bacteria Neisseria meningitidis cause most meningococcal disease, which can lead to meningitis and blood infections. It identifies who is at increased risk of getting the disease, and describes transmission and effects. It discusses the meningococcal conjugate vaccine (MenACWY) and the meningococcal polysaccharide vaccine (MPSV4), who should receive which vaccine, and when. It identifies who should not get vaccinated, risks and side effects, and what to look for and what to do in the event of a severe allergic reaction. Contact information for the National Vaccine Injury Compensation Program (VICP) is provided, along with tips for how people can learn more about meningococcal ACWY vaccines.
The English-language VIS was created by the Centers for Disease Control and Prevention (CDC) National Center for Immunization and Respiratory Diseases. The translations are provided by the Immunization Action Coalition (IAC) and its partner organizations. The Arabic, Chinese - simplified, Chinese - traditional, French, Russian, Somali, Spanish, Turkish, and Vietnamese translations are updated to the August 2018 VIS; the other translations from IAC are based on the 03/31/2016 CDC version. The August 2018 VIS for MenACWY has changed from the 2016 version in that references to meningococcal polysaccharide vaccine (MPSV4), which is no longer available in the United States, have been removed. Otherwise, changes from the 2016 VIS are minimal.
A qualified translation company performed an independent review by a second translator, and a client advocate.